RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
  CAD
  CHF
  Clinical Trials
  Hypertension
   Pulmonary Hypertension
  Myocardial Infarction
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Editorial
Hypertension Channel

subscribe to Hypertension newsletter
Latest Research : Cardiology : Hypertension

   EMAIL   |   PRINT
Need for a revamp of hypertension treatment

May 25, 2009 - 2:12:04 AM , Reviewed by: Dr. Sanjukta Acharya

 
[RxPG] In the British Medical Journal May 23rd 2009 issue, the findings of a meta-analysis by Law and Colleagues has been published. The chief findings are that ß blockers are as effective as other blood pressure medication. Also, they found that regardless of the pre-treatment blood pressure, there was a reduction in cardiovascular risk in patients treated with anti-hypertensive medication who had a reduction in systolic or diastolic blood pressure.
The meta-analysis included 147 trial reports. In the trials that compared ß blockers in individuals with a history of coronary heart disease(CHD), with placebo or untreated control group, CHD was reduced by 29%. This was significantly different from groups on ß blockers without a history of CHD, or even those on other anti-hypertensive medication with or without a history of coronary heart disease, where the reduction was 15%. A 31% risk reduction was observed with the use of ß blockers in patients recruited immediately after a myocardial infarction, with only a 13% risk reduction in CHD when ß blockers were used in other circumstances.
The meta-analysis showed that using any of the five main categories of blood pressure medications (thiazides, ß blockers, Calcium Channel Blockers (CCBs), Angiotensin Converting Enzyme(ACE) inhibitors and Angiotensin Receptor Blockers(ARBs) ) to reduce the systolic blood pressure by 10 mmHg or the diastolic blood pressure by 5 mm Hg , resulted in a 22% reduction in CHD events and a 41% reduction in stroke.
Calcium channel blockers were found to reduce the risk of stoke by 33% compared to the overall reduction of 27% by all groups of anti-hypertensive medication.
The authors have also suggested that using three drugs at half standard dose would produce a greater reduction in risk of CHD and stroke than one drug at standard dose. This is an estimate and would need trials to further validate this.
Their finding that there was a reduction in risk for a specified change in blood pressure, independent of a person’s baseline blood pressure, would now cause us to wonder about blood pressure targets and their validity. “Lower the better” seems the way forward as suggested by the authors. The choice of anti-hypertensive drugs is also less important, except in acute myocardial infarction where ß Blockers have shown to be superior and in stroke where CCBs are preferred. Certain populations have not been specifically looked at in this meta-analysis and one would continue to choose ACE inhibitors and ARBs to treat end stage renal failure patients to protect residual renal function till further studies suggest otherwise. The choice of medication in the general population, therefore, would be determined by the side effects of the medication and that of the lowest blood pressure an individual can tolerate safely. Obviously, this is going to be a point of discussion for sometime to come.



Publication: BMJ May 23 2009

Advertise in this space for $10 per month. Contact us today.


Related Hypertension News
Osmoreceptors in liver help increase blood pressure
Renal sympathetic nerve ablation may cure high blood pressure
Kids with hypertension more likely to fumble in studies
Need for a revamp of hypertension treatment
Scientists switch off nerves to treat high blood pressure
Low potassium levels likely to trigger high blood pressure
BP response to stress can point to better treatment
Statins may help lower blood pressure
Now a new way to regulate blood pressure
Posture linked to blood pressure

Subscribe to Hypertension Newsletter

Enter your email address:


 About Dr. Sanjukta Acharya
This news story has been reviewed by Dr. Sanjukta Acharya before its publication on RxPG News website. Dr. Sanjukta Acharya, MBBS MRCP is the chief editor for RxPG News website. She oversees all the medical news submissions and manages the medicine section of the website. She has a special interest in nephrology. She can be reached for corrections and feedback at [email protected]
RxPG News is committed to promotion and implementation of Evidence Based Medical Journalism in all channels of mass media including internet.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)